Net cost differences were AU$4.2 billion for SGLT2is and AU$20.2 billion for GLP-1 RAs, and the ICERs were AU$23,717 and AU$100,705 per QALY gained, respectively
Josie changed everything
Whilst it is good news that evidence from the real world on the benefits of semaglutide supports results from clinical trials, the global shortage of these drugs remains an issue
Media: +1 (212) 733-1226 [email protected] Investor: +1 (212) 733-4848 [email protected] Source: Pfizer Inc.
This article explains the current status of the MDL, key legal developments, medical findings, and what claimants can do to strengthen their lawsuits
Please consult your physician before use if you are pregnant or nursing, under the age of 18, or are undergoing treatment for a medical condition